Efficacy and safety of pembrolizumab for treating advanced non-small-cell lung cancer: a meta-analysis of phase II and III randomized controlled trials-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Efficacy and safety of pembrolizumab for treating advanced non-small-cell lung cancer: a meta-analysis of phase II and III randomized controlled trials

Published:2021-12-13 Issue: Volume: Page:1-9
ISSN:1120-009X
Container-title:Journal of Chemotherapy
language:en
Short-container-title:Journal of Chemotherapy

Author:

Gong Tianyao¹,Liu Lei²,Liu Yufei³,Liu Ke³,Yang Yang³,Li Liuying⁴,Zhang Chuantao³

Affiliation:

1. College of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, China

2. Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

3. Department of Respiratory Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China

4. Department of Integrated Chinese and Western Medicine, The First People’s Hospital of Zigong City, Zigong, Sichuan, China

Publisher

Informa UK Limited

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology,Oncology

Link

https://www.tandfonline.com/doi/pdf/10.1080/1120009X.2021.2014714

Reference20 articles.

1. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

2. Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer

3. Acquired resistance to TKIs in solid tumours: learning from lung cancer

4. Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

5. Programmed death ligand-1 expression in non-small cell lung cancer

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP